These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14695041)

  • 21. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.
    Fishbane S; Durham JH; Marzo K; Rudnick M
    J Am Soc Nephrol; 2004 Feb; 15(2):251-60. PubMed ID: 14747371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-induced nephropathy.
    Rundback JH; Nahl D; Yoo V
    J Vasc Surg; 2011 Aug; 54(2):575-9. PubMed ID: 21741789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
    Kini AS; Mitre CA; Kamran M; Suleman J; Kim M; Duffy ME; Marmur JD; Sharma SK
    Am J Cardiol; 2002 Apr; 89(8):999-1002. PubMed ID: 11950448
    [No Abstract]   [Full Text] [Related]  

  • 24. Current trials of interventions to prevent radiocontrast-induced nephropathy.
    Asif A; Garces G; Preston RA; Roth D
    Am J Ther; 2005; 12(2):127-32. PubMed ID: 15767830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.
    Chamsuddin AA; Kowalik KJ; Bjarnason H; Dietz CA; Rosenberg MS; Gomes MD; McDermott CM; Hunter DW
    AJR Am J Roentgenol; 2002 Sep; 179(3):591-6. PubMed ID: 12185025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrast-associated nephropathy.
    Soma VR; Cavusoglu E; Vidhun R; Frishman WH; Sharma SK
    Heart Dis; 2002; 4(6):372-9. PubMed ID: 12441014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
    Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
    Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetylcysteine and fenoldopam. Promising new approaches for preventing effects of contrast nephrotoxicity.
    Thompson EJ; King SL
    Crit Care Nurse; 2003 Jun; 23(3):39-46. PubMed ID: 12830779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease.
    Shavit L; Korenfeld R; Lifschitz M; Butnaru A; Slotki I
    J Interv Cardiol; 2009 Dec; 22(6):556-63. PubMed ID: 19732281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast-induced nephropathy remains a serious complication of PCI.
    Mehran R
    J Interv Cardiol; 2007 Jun; 20(3):236-40. PubMed ID: 17524117
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention of contrast-induced renal dysfunction by N-acetylcysteine. Truth or myth?
    Billinger M; Hess OM; Meier B
    Eur Heart J; 2004 Feb; 25(3):188-9. PubMed ID: 14972417
    [No Abstract]   [Full Text] [Related]  

  • 33. [New usage for an old drug: acetylcysteine for contrast-induced nephropathy].
    Asher I; Hammerman A; Sthoeger Z
    Harefuah; 2005 Sep; 144(9):642-6; 675. PubMed ID: 16218537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-acetylcysteine and/or theophylline as a preventive measure for contrast agent induced nephropathy: we should use better markers for detection of renal function.
    Schultz MJ
    Radiology; 2007 Dec; 245(3):918-9; author reply 918-9. PubMed ID: 18024462
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    Subramaniam RM; Suarez-Cuervo C; Wilson RF; Turban S; Zhang A; Sherrod C; Aboagye J; Eng J; Choi MJ; Hutfless S; Bass EB
    Ann Intern Med; 2016 Mar; 164(6):406-16. PubMed ID: 26830221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy.
    Guru V; Fremes SE
    Clin Nephrol; 2004 Aug; 62(2):77-83. PubMed ID: 15356963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrast-induced nephropathy: a review.
    Sanaei-Ardekani M; Movahed MR; Movafagh S; Ghahramani N
    Cardiovasc Revasc Med; 2005; 6(2):82-8. PubMed ID: 16263365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis.
    Duong MH; MacKenzie TA; Malenka DJ
    Catheter Cardiovasc Interv; 2005 Apr; 64(4):471-9. PubMed ID: 15789388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetylcysteine for the prevention of radiocontrast -induced nephropathy.
    Tepel M
    Minerva Cardioangiol; 2003 Oct; 51(5):525-30. PubMed ID: 14551521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of radiocontrast nephropathy.
    Lin J; Bonventre JV
    Curr Opin Nephrol Hypertens; 2005 Mar; 14(2):105-10. PubMed ID: 15687835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.